Skip to content
‹ Back to IndustriesSciences

The Industry That is Depending on Science and Regulation to Grow

Yuran Li, Director of MS Commercial Strategies at Alternative Biomedical Solutions, plays a pivotal role in cannabis testing and method development, addressing the complexities of cannabis as a consumable product. As more states legalize cannabis, rigorous testing is necessary to ensure safety and proper labeling due to the plant's tendency to absorb harmful substances like pesticides and heavy metals.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Jason Claybrook · · Alternative Biomedical SolutionsCannabinoidCannabisCannabis Testing
Share
The Industry That is Depending on Science and Regulation to Grow

Key takeaways

01

Alternative Biomedical Solutions is a pioneer in cannabis method development and testing.

02

Yuran Li emphasizes the importance of rigorous cannabis testing due to its unique absorption of pesticides and heavy metals.

03

Different states have varied laws on cannabis sales, making it essential to understand individual state regulations.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Yuran Li, Director, MS Commercial Strategies, Alternative Biomedical Solutions (ABS), is a biochemist by training. Still, his fascinations with physics, math, and probability have led him down some interesting paths, including some stints in the professional poker world. Lucky for ABS, he chose the science route.

Cannabis is a schedule 1 drug classification by the U.S. Federal government. As more and more states legalize it, there is a growing need for reliable testing to ensure the safety and potency of cannabis products. ABS is one of the pioneers in cannabis method development and testing. Li spoke with Jason Claybrook on some of ABS’s activities surrounding Cannabis.

Any product that people consume goes through testing to ensure their safety. “Cannabis is unique in that it’s ultimately a weed,” Li said. And it can prove quite a challenge to cultivate because the plant can soak up a lot of pesticides and other elements used for pest control. “Additionally, the Cannabis plant itself also uptakes quite a lot of heavy metals, things like arsenic and lead.” Accumulation of these pollutants can harm humans, so accurate testing is essential.

Some of the testing ABS does on Cannabis is to look for micro toxins, like mold and soil pollutants. And from a marketing and regulatory standpoint, they test for potency. In some cases, testing can help ensure that a strain grown for CBD does not contain THC. One challenge Li cautioned is every state has different guidelines, and it is essential to understand the laws governing each state where Cannabis sales are allowed.

Another aspect of lab testing that is becoming more and more important for Cannabis is label testing. As with craft beers and whiskey, labels need to back up their product’s claims. Testing ensures the strain offered on the label is the strain received by the consumer.

Breaking through ‘Pilot Purgatory’ in Innovating New Solutions

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

JC
Jason Claybrook
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick have developed a version of two-dimensional mass spectrometry called Q-2DMS. Until now, only the best-funded centers could afford 2DMS hardware, and Verdel's chief executive argues that the field lacked access, not an understanding of what the method can do. If 2DMS moves onto more common hardware, more labs could evaluate it. Published results show up to tenfold more usable spectral information on closely related or near-isobaric compounds, the look-alike molecules that separation and filtering tend to blur together or drop.

  • 01The reported gain of up to tenfold more usable spectral information applies to closely related or near-isobaric compounds, so the best trial samples are the mixtures chromatography struggles to separate.
  • 02A complete time-stamped record can be revisited after a sample runs out or degrades, and a full acquisition could, in principle, let archived runs address new questions later.

Oct 9, 2026

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

YL
Yuran Li

Director, MS Commercial Strategies

Alternative Biomedical Solutions (ABS)

Yuran Li is a biochemist by training with a fascination for physics, math, and probability, and has had professional experience in the poker world. At ABS, he plays a key role in cannabis method development and testing.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512